嵌合抗原受体T细胞治疗的临床应用

Clinical application of chimeric antigen receptor T cells

嵌合抗原受体（CAR）T细胞在部分白血病及淋巴瘤上的显著治疗效果使人们认识到转基因过继性细胞免疫治疗可能是治疗实体瘤和血液病的突破之一.文章回顾了CAR内源性细胞在肿瘤微环境的功能抑制状况、各个分子模块的分子生物学功能、CAR-T细胞在临床应用方面遇到的困难和解决策略,以及如何提高临床治疗效果并减少不良反应,使癌症免疫疗法能更好地应用到肿瘤治疗中.

Chimeric antigen receptor （CAR） T cell shows its significant therapeutic effect in part of leukemia and lymphomas, which indicates that transgenic adoptive cellular immunotherapy may be one of the breakthroughs in treatment of solid tumors and blood diseases. The functional inhibition of CAR endogenous cells in the tumor microenvironment , molecular biology function of molecules, difficulties of CAR T cells in clinical application and the solutions , how to improve the clinical efficacy and to reduce toxic side effects for future cancer immunotherapy in clinic are reviewed in this paper.